BioXcel Therapeutics
BTAI
47 hedge funds and large institutions have $8.69M invested in BioXcel Therapeutics in 2026 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
19% more capital invested
Capital invested by funds: $7.28M → $8.69M (+$1.41M)
18% more funds holding
Funds holding: 40 → 47 (+7)
4.88% less ownership
Funds ownership: 24.88% → 20% (-4.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCM
Oaktree Capital Management
Los Angeles,
California
|
+$1.33M |
| 2 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$834K |
| 3 |
OFA
Oaktree Fund Advisors
Los Angles,
California
|
+$237K |
| 4 |
Millennium Management
New York
|
+$208K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$175K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.56M |
| 2 |
Man Group
London,
United Kingdom
|
-$129K |
| 3 |
Jones Financial Companies
Des Peres,
Missouri
|
-$80.4K |
| 4 |
Morgan Stanley
New York
|
-$10.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.75K |
BTAI Hedge Fund Activity: Q2 2026 in Review
47 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q2 2026, worth a combined $8.69M — up 19% from $7.28M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new BTAI positions and 3 closed out — a net gain of 7 holders — while 12 added to existing stakes and 8 trimmed.
The largest buyer was Oaktree Capital Management, adding an estimated $1.33M. The largest seller was Armistice Capital, exiting entirely with an estimated $2.56M sold.
- 47 institutional investors held BioXcel Therapeutics (BTAI) as of Q2 2026, up from 40 in Q1 2026.
- Funds reported $8.69M of BioXcel Therapeutics stock for Q2 2026, up 19% quarter-over-quarter.
- 10 funds opened new BioXcel Therapeutics positions in Q2 2026 and 3 closed out, a net change of +7 holders.
- The largest BioXcel Therapeutics buyer in Q2 2026 was Oaktree Capital Management, an estimated $1.33M added.
- The largest BioXcel Therapeutics seller in Q2 2026 was Armistice Capital, an estimated $2.56M sold.
Based on aggregated 13F filings for Q2 2026.